ECDB-Endometrial cancer gene database

REFERENCES

Gene Name	Gene ID	Pubmed ID	Classification	Mechanism	Marker	Type	Normal Cases	Disease Cases	Age	Mean Age	Place	FIGO	Grade	Remark	Title	Journal	Volume	Year
SFN	2810	16243811	Endometrial Adenocarcinoma	Down regulation/ Down expression	Prognostic Marker	Tumor suppressor	25 (15 proliferative phase and 10 seceretory phase)	103	-	-	Tohoku University Hospital; Sendai; Japan	I (n=66); II (n=12); III (n=22); IV (n=3)	1 (n=49); 2 (n=32); 3 (n=22)	[1] Loss or absence of 14-3-3sigma determined by immunohistochemistry may be an important tool to identify endometrial carcinoma cases at high risk of recurrence and/or death; who are otherwise not detected by current clinical and pathologic evaluation; especially in the early stages of the disease. [2] A statistically significant correlation between loss of 14-3-3sigma expression and adverse clinical outcome of the patients (P = 0.0007). In the early stages of cancer (stages I and II); 14-3-3sigma immunoreactivity was absent in 5 of 10 (50.0%) patients who showed recurrence during follow-up; whereas its absence was detected in only 13 of 68 (19.1%) disease-free patients in the same period. In addition; 14-3-3sigma immunoreactivity was absent in 4 of 5 (80.0%) patients who died; whereas its absence was detected in only 14 of 73 (19.2%) patients who had lived during the same period. Patients whose tumors were negative for 14-3-3sigma were at much greater risk to develop recurrent and/or mortal disease (P = 0.0372 and 0.0067). [3] Results of 14-3-3sigma immunohistochemistry in the early stage of endometrial carcinoma could contribute to planning postoperative follow-up and adjuvant therapy.	14-3-3sigma in endometrial cancer--a possible prognostic marker in early-stage cancer.	Clinical Cancer Research	11(20):7384-91	2005
SFN	2810	15930340	-	Differentially expressed		-	-	119 (66 endometrioid; 24 papillary serous; 29 mixed mullerian tumors)	-	-	Duke University Medical Centre; North Carolina	-	-	[1] The microarray study shows that this gene is differently expressed in endometrioid carcinoma profile; reflecting expression value 2.035 and 3.538 on both the endometrioid versus papillary serous carcionma and endometrioid versus mixed mullerian tumor respectively.	Microarray analysis of endometrial carcinomas and mixed mullerian tumors reveals distinct gene expression profiles associated with different histologic types of uterine cancer	Clinical Cancer Research	11(11):4056-66	2005